Rodman & Renshaw has recently initiated Monopar Therapeutics Inc (MNPR) stock to Buy rating, as announced on October 11, 2024, according to Finviz. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Monopar Therapeutics Inc (MNPR) Stock Trading Recap
On Thursday, Monopar Therapeutics Inc (MNPR) stock saw a modest uptick, ending the day at $32.66 which represents a slight increase of $28.03 or 605.40% from the prior close of $4.63. The stock opened at $5.12 and touched a low of $4.87 during the day, reaching a high of $38.5. The volume of shares traded was 19.49 million exceeding the average volume of 0.81 million.
Sponsored
MNPR Stock Performance and Moving Averages
In recent trading, Monopar Therapeutics Inc (MNPR) stock price has shown some volatility, fluctuating 471.98% over the last five trades and 531.72% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 940.96%, and it has gained 807.22% in the previous three months. Currently, MNPR is trading at 389.03%, 613.44%, and 800.84% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, MNPR, a Healthcare sector stock, is trading 277.57% below its 52-week high but remains 2284.81% above its 52-week low. The Average True Range (ATR) (14 days) of 2.94 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Monopar Therapeutics Inc’s Profitability and Valuation Ratios
Monopar Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.00% with a gross margin of 940.96%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Monopar Therapeutics Inc’s market capitalization stands at $114.96 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Book Ratio is 18.88, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 49.91% of Monopar Therapeutics Inc (MNPR)’s shares, while financial institutions hold 2.16%.
